Search Within

Genitourinary Oncology Service

Formats
  1. Journal Article (2795)
  2. Meeting Abstract (2525)
  3. Review (121)
  4. Book Section (83)
  5. Editorial (57)
  6. Correspondence (34)
  7. Conference Paper (29)
  8. Guidelines (25)
  9. Research Letter (18)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Solid Tumor Oncology Division (5695)
  2. Department of Medicine (5685)
  3. GSK Faculty (1658)
  4. Human Oncology and Pathogenesis Program (1157)
  5. Department of Pathology and Laboratory Medicine (1129)
  6. Surgery (1021)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. David Solit (785)
  4. Dean Bajorin (664)
  5. Michael Morris (588)
  6. Jonathan Rosenberg (525)

More People

Years
  1. 2025 (203)
  2. 2024 (294)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1713)
  2. Annals of Oncology (304)
  3. Clinical Cancer Research (283)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (123)

More Publications

Publishers
  1. American Society of Clinical Oncology (1780)
  2. American Association for Cancer Research (689)
  3. Oxford University Press (414)
  4. Elsevier Science, Inc. (396)
  5. Elsevier Inc. (380)
  6. Nature Publishing Group (304)

More Publishers

Results (5695)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses
    Meeting Abstract

    Abida, W.; Campbell, D.; Patnaik, A.; Sautois, B.; Shapiro, J.; Vogelzang, N. J.; Bryce, A. H.; McDermott, R.; Ricci, F.; Rowe, J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Results from a randomised phase I/II trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Voss, M. H.; Azad, A. A.; Hansen, A. R.; Gray, J. E.; Welsh, S. J.; Achour, I.; Hu, H.; Lewis, L.; Walcott, F. L.; Oosting, S. F.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis
    Meeting Abstract

    Uemura, M.; Tomita, Y.; Miyake, H.; Hatakeyama, S.; Kanayama, H. O.; Numakura, K.; Takagi, T.; Kato, T.; Eto, M.; Obara, W.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: Comprehensive tumour genomic and transcriptomic analyses
    Meeting Abstract

    Ravaud, A.; Martini, J. F.; Ching, K.; Staehler, M.; Magheli, A.; Escudier, B.; Mu, X. J.; Valota, O.; Lin, X.; Motzer, R. J.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Pal, S. K.; Bajorin, D. F.; Hoffman-Censits, J. H.; Quinn, D. I.; Petrylak, D. P.; Galsky, M. D.; Vaishampayan, U. N.; De Giorgi, U.; Gupta, S.; Burris, H. A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Quality of life of metastatic urothelial cancer (mUC) patients treated with enfortumab vedotin (EV) following platinum-containing chemotherapy and a checkpoint inhibitor (CPI): Data from EV-201 cohort 1
    Meeting Abstract

    McGregor, B. A.; O'Donnell, P. H.; Balar, A.; Petrylak, D. P.; Rosenberg, J. E.; Yu, E.; Quinn, D. I.; Shah, S. N.; Pinelli, J.; Hepp, Z.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
    Meeting Abstract

    George, D. J.; Casey, M.; Degtyarev, E.; Lechuga Frean, M. J.; Aimone, P.; Ravaud, A.; Halabi, S.; Motzer, R. J.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
    Meeting Abstract

    Janjigian, Y. Y.; Maron, S.; Chou, J. F.; Gabler, A. R.; Simmons, M. Z.; Momtaz, P.; Shcherba, M.; Ku, G. Y.; Won, E.; Sanchez-Vega, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Phase II trial of SM 88 in non-metastatic biochemical recurrent prostate cancer
    Meeting Abstract

    Gartrell, B.; Del Priore, G.; Retter, A.; Chen, W. T.; Sokol, G. H.; Vandell, A.; Roach, M.; Scher, H. I.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)
    Meeting Abstract

    Chi, K. N.; Rathkopf, D.; Attard, G.; Smith, M. R.; Efstathiou, E.; Olmos, D.; Small, E. J.; Lee, J. Y.; Sieber, P.; Dunshee, C.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save